Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Most statements are general about antipsychotics (not specifically supported by the provided VRAYLAR label excerpts). The excerpts supplied mainly address boxed warnings for elderly dementia-related psychosis and suicidal thoughts/behaviors language in the context of antidepressant trials, plus geriatric use; therefore many claims are unsupported or not assessable from the supplied label text. No explicit dosing/administration, contraindications, or detailed interaction information is provided in the excerpts, limiting support for those claims.
Category Scores
Accurate Statements
Cariprazine is an antipsychotic medicine.
Consistent with the provided label excerpts referencing antipsychotic drugs and VRAYLAR.
Patients are generally advised to seek urgent medical help for severe allergic reactions.
Not specifically supported or refuted by the supplied excerpts (no direct text provided addressing allergic reactions). Marked as 'accurate' only as a generic safety counsel, but the label excerpts do not provide support.
Unsupported Statements
Cariprazine is used to treat certain psychiatric conditions.
Indications are not provided in the supplied label excerpts.
Cariprazine is used to treat schizophrenia.
No indication text for schizophrenia is present in the supplied excerpts.
Cariprazine is used to treat bipolar disorder.
No indication text for bipolar disorder is present in the supplied excerpts.
In bipolar disorder, cariprazine is used for manic episodes.
No label indication or bipolar dosing/episode language is present in the supplied excerpts.
Depending on the approved indication, cariprazine is used for depressive episodes in bipolar disorder.
No label indication text for bipolar depressive episodes is present in the supplied excerpts.
Cariprazine acts on dopamine and serotonin receptors.
Mechanism/receptor activity is not included in the supplied excerpts.
Cariprazine’s receptor profile contributes to its effects on psychotic symptoms in schizophrenia.
No receptor mechanism or schizophrenia efficacy language is included in the supplied excerpts.
Cariprazine’s receptor profile contributes to its effects on mood symptoms in bipolar disorder.
No receptor mechanism or bipolar efficacy language is included in the supplied excerpts.
Common side effects of antipsychotics include sleepiness or sedation.
No adverse reaction list specific to VRAYLAR or antipsychotic class effects is included in the supplied excerpts.
Common side effects of antipsychotics include restlessness (akathisia).
No adverse reaction list for VRAYLAR is included in the supplied excerpts.
Common side effects of antipsychotics include movement-related effects.
No adverse reaction content in the supplied excerpts supports this statement.
Weight change can occur with antipsychotics.
No label excerpt addressing weight change is provided.
Cariprazine is an oral medication taken by mouth.
The supplied excerpts do not include dosage form/route details.
Cariprazine dosing schedule and strength depend on the specific condition being treated.
Dosage and administration information is not provided in the supplied excerpts.
Cariprazine dosing schedule and strength depend on the country’s approved prescribing information.
The supplied excerpts do not address international labeling variability.
Antipsychotic medicines often show symptom improvement over days to weeks.
No onset/efficacy timing language is included in the supplied excerpts.
Full effects of antipsychotic medicines can take longer than days to weeks.
No efficacy onset timing language is included in the supplied excerpts.
Cariprazine’s clinical onset can vary by symptom type.
No onset by symptom type language is included in the supplied excerpts.
Patients are generally advised to seek urgent medical help for signs of serious movement problems.
No Warnings/precautions text about movement problems is provided in the supplied excerpts.
Patients are generally advised to seek urgent medical help for severe worsening of psychiatric symptoms.
The supplied excerpt about suicidal thoughts/behaviors concerns monitoring during antidepressant trials; it does not provide broad 'worsening psychiatric symptoms' urgent advice for VRAYLAR use.
Cariprazine’s metabolism can make it sensitive to other medicines that affect the same metabolic pathways.
No drug metabolism or interaction mechanism language is included in the supplied excerpts.
Interaction risk for cariprazine depends on the patient’s complete medication list.
No interaction guidance is included in the supplied excerpts.
Cariprazine interaction risk depends on concurrent use of antidepressants.
No drug interaction section excerpt is provided.
Cariprazine interaction risk depends on concurrent use of antifungals.
No drug interaction section excerpt is provided.
Cariprazine interaction risk depends on concurrent use of antibiotics.
No drug interaction section excerpt is provided.
Cariprazine interaction risk depends on concurrent use of seizure medicines.
No drug interaction section excerpt is provided.
Cariprazine availability and branding depend on the market.
No label excerpt addresses branding/market availability.
The manufacturer and brand name can differ across countries.
No label excerpt addresses branding/market availability.
The active ingredient of cariprazine is the same across countries.
No label excerpt addresses cross-country equivalence.
Contradictions
Important Omissions
Elderly patients with dementia-related psychosis: VRAYLAR is not approved and has an increased risk of death (boxed warning details such as increased risk ratio and death rates) and cerebrovascular adverse reactions including stroke/TIA.
Importance:
Moderate
Suicidal thoughts and behaviors monitoring language is specific to antidepressant trials context (ages 24 years and younger) and counsel/monitoring recommendations for clinical worsening and emergence of suicidal thoughts/behaviors.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Because many statements are unsupported by the supplied label excerpts (including indications, route, dosing, and interactions), the main safety relevance cannot be confirmed from the provided text. The response does not include the supplied boxed warning details about increased mortality/stroke in dementia-related psychosis, which are material omissions relative to the provided excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Most claims are not supported by the specific FDA label excerpts provided (indications, mechanism, adverse effects, route, dosing, and drug interactions are not present). Material boxed-warning information in the excerpts (dementia-related psychosis mortality and stroke/TIA) is omitted.
Suggested Improvement
Limit statements to what is supported by the provided label excerpts (increased mortality and lack of approval for dementia-related psychosis; cerebrovascular adverse reactions; geriatric caution language; suicidal thoughts/behaviors monitoring language in the provided context) and avoid adding uncited details about indications, receptor mechanisms, side effects, dosing, and interactions unless corresponding label sections are supplied.